The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

IriSys awarded five-year contact by NCI

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

IriSys LLC was awarded a five-year contract worth up to $3 million by the NCI Developmental Therapeutic Program of the Division of Cancer Treatment and Diagnosis for the pharmaceutical development and production of new therapeutic agents for use in clinical trials supported by NCI. Under this agreement, IriSys will be supplying NCI with oral, topical...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Login

Site license subscribers:
Log in with your IP | Register a sponsored account